Literature DB >> 3131260

Enhancement of interleukin 2 production by quinolone-treated human mononuclear leukocytes.

Y Roche1, M Fay, M A Gougerot-Pocidalo.   

Abstract

Previous studies have shown that lectin-induced human mononuclear leukocyte (MNL) proliferation was influenced by quinoline derivative antibiotics (quinolones), depending on both the dose and the antimicrobial agent used. Since the production of interleukin-2 (IL-2) is known to be involved in the proliferation of immune cells, we investigated the effects of three quinolones: ciprofloxacin (Cip), ofloxacin (Ofl) and pefloxacin (Pef) on IL-2 production in vitro by phytohemagglutinin (PHA)-stimulated human MNL. IL-2 activity in the supernatants of PHA-stimulated MNL was found to be enhanced by quinolones in a dose- and time-dependent manner. Increased IL-2 activity was observed using Cip, Ofl or Pef at therapeutically achievable blood concentrations (5-10 micrograms/ml). Since at these concentrations the PHA-induced proliferative response of MNL was not impaired by quinolones, the increased recovered IL-2 activity was not related to a decreased absorption of IL-2 by activated MNL. At high antibiotic concentrations (25 micrograms/ml), the enhanced IL-2 activity might be related (i) to increased accumulation resulting from the decreased proliferation induced by the quinolones at these concentrations, and (ii) to a true increased IL-2 production by the cells. In fact, an increased IL-2 recovery in presence of quinolones was always observed after blocking the cell cycle by mitomycin C, and was therefore independent of DNA-synthesis. Furthermore, the expression of IL-2 receptors was not modified by Cip, Ofl or Pef. These data show that quinolones increased IL-2 synthesis by MNL and suggest the potential usefulness of these antibiotics, not only as antimicrobial agents, but also as modulators of immune responses.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3131260     DOI: 10.1016/0192-0561(88)90091-4

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  6 in total

1.  Selective enhancement of synthesis of interleukin-2 in lymphocytes in the presence of ciprofloxacin.

Authors:  K Riesbeck; A Forsgren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

Review 2.  Immunological aspects of new quinolones.

Authors:  I Shalit
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

3.  In vivo effects of rufloxacin and ciprofloxacin on T-cell subsets and tumor necrosis factor production in mice infected with Bacteroides fragilis.

Authors:  S V Gollapudi; S K Chuah; T Harvey; H D Thadepalli; H Thadepalli
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

4.  Ciprofloxacin treatment in vivo increases the ex vivo capacity of lipopolysaccharide-stimulated human monocytes to produce IL-1, IL-6 and tumour necrosis factor-alpha.

Authors:  S Bailly; M Fay; B Ferrua; M A Gougerot-Pocidalo
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

5.  Ciprofloxacin does not inhibit mitochondrial functions but other antibiotics do.

Authors:  K Riesbeck; A Bredberg; A Forsgren
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

6.  Ciprofloxacin enhances T cell function by modulating interleukin activities.

Authors:  K G Stünkel; G Hewlett; H J Zeiler
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.